Market Overview

UPDATE: Bank of America Raises PO to $40 on Integra Lifesciences

Related IART
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed
Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B

Bank of America Merrill Lynch reiterates a Neutral rating on Integra Lifesciences (NASDAQ: IART) and raises its price objective from $36 to $40.

Bank of America Merrill Lynch comments, “Raising PO to $40 We are raising our PO on IART to $40 from $36 primarily due to the recent signs of stabilization and/or strength in IART's most important orthopedic growth markets (extremities/spine) that we have documented in recent notes on Biomet and ZMH. Additionally, IART, like many US-focused small cap device names, would benefit in a disproportionate way if the Supreme Court declares President Obama's healthcare reform law unconstitutional this week (a decision is expected Thursday 6/28).”

Integra Lifesciences closed at $35.74 yesterday.

Latest Ratings for IART

Nov 2015CitigroupInitiates Coverage onBuy
Sep 2015Bank of AmericaUpgradesNeutralBuy
Jul 2015JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color News Price Target Politics Legal Analyst Ratings General


Related Articles (IART)

Get Benzinga's Newsletters